A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable

NCT01739218 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Bevacizumab

Sponsor

Hoffmann-La Roche